Davide Capodanno
EuroIntervention Editor-in-Chief
Latest contributions
Publishing in interventional cardiology: aligning authors, editors and impact
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive perspective on publishing in interventional cardiology by aligning the expectations of authors, editors, reviewers, and readers. It addresses differences in paper interpretation, common misalignments between scientific intent and editorial outcomes, and strategies to enhance clarity, relevance, and impact of scientific publications.
Insight from new evidence for complex PCI: value of imaging (CHIP IVUS) and left ventricular support (CHIP BCIS 3)
21 May 2026 – From EuroPCR 2026
This session reviews the impact of recent evidence on complex PCI, highlighting the value of intracoronary imaging (CHIP IVUS trial) and left ventricular assist devices (CHIP BCIS 3 trial). Through case discussions, participants reflect on how these innovations influence daily clinical practice and enhance procedural planning...
Spotlight - TAVI durability: contemporary evidence and future directions
21 May 2026 – From EuroPCR 2026
Focusing on TAVI durability, this session reviews recent clinical evidence from randomized trials and large registries, examining procedural and device-related factors influencing long-term valve performance. It also discusses challenges in follow-up and implications for future trial designs and device monitoring.
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
Expanding the horizon - Trials addressing unchartered territories in coronary and structural heart
20 May 2026 – From EuroPCR 2026
New clinical evidence is pushing coronary and structural heart therapy into areas that were previously uncertain or inconsistently defined, with multiple landmark trials now shaping future practice.
Among the studies discussed in this EuroPCR 2026 session, are SORT OUT XII, START YOUNG, BISCUSPID, LANDMARK 2 and RESTORE...
Major Late-Breaking Trials from EuroPCR 2026
20 May 2026 – From EuroPCR 2026
This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.
Rethinking coronary artery disease: from ischaemia to atheroma - Implications of the Lancet Commission for Interventional Cardiology
20 May 2026 – From EuroPCR 2026
This session invites a re-evaluation of coronary artery disease by shifting focus from ischemia to atheroma, integrating insights from the Lancet Commission for Interventional Cardiology. It explores the significance of plaque burden, biology, and inflammation in guiding PCI decisions and outlines the future role of PCI...
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
New evidence for pharmacology for coronary artery disease
19 May 2026 – From EuroPCR 2026
This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus...
TAVI in patients with concomitant valve and coronary artery disease
17 Nov 2025 – From PCR London Valves 2025
Focused on patients with concomitant valve and coronary artery disease, this session examines evaluation strategies for aortic stenosis burden, integrates recent trial data on combined TAVI and PCI, and discusses optimal management approaches in complex multi-valve disease scenarios through detailed case presentations and clinical outcomes.
How to manage patients with aortic stenosis and coronary artery disease?
04 Mar 2026 – From PCR London Valves 2025
Tiffany Patterson and Davide Capodanno address the increasingly common scenario of managing coronary artery disease (CAD) in patients undergoing TAVI. With up to half of TAVI candidates presenting with CAD, they highlight new evidence from NOTION-3 showing that revascularization reduces major adverse cardiac events. The takeaway:...
Alain Cribier EuroIntervention Award
16 Nov 2025 – From PCR London Valves 2025
This session honors the legacy and contributions of Alain Cribier through the EuroIntervention Award, recognizing excellence and innovation in interventional cardiology. It reflects on the advancements inspired by Dr. Cribier's pioneering work and highlights key achievements in the field.
Late-breaking evidence in structural and coronary interventions - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...
EuroIntervention Achieves Record Impact Factor of 9.5
25 Jun 2025
Toulouse, FRANCE: Clarivate, publisher of the Journal Citation Reports (JCR) has announced the new Impact Factor for EuroIntervention of 9.5, putting it in the top percentile of academic publications published today.
Celebrating 20 years of EuroIntervention!
22 May 2025
According to Editor-in-Chief, Davide Capodanno, EuroIntervention marks this milestone by continuing its upward trajectory, blending cutting-edge and traditional elements to bring the latest data to its readers faster than ever before.
Author
Understanding research: insights from a groundbreaking study
22 May 2025 – From EuroPCR 2025
Enhance your understanding of contemporary research in PCI versus CABG with this session. Learn foundational research principles, latest study findings, and how to translate evidence into clinical practice to improve patient communication and outcomes, bridging the gap between research and everyday cardiology care.
What an interventional cardiologist should know about anti-thrombotics
22 May 2025 – From EuroPCR 2025
This session provides comprehensive knowledge on anti-thrombotic management for interventional cardiologists, emphasizing effective inhibition during acute STEMI, latest evidence implementation for high bleeding risk patients, and customization of dual antiplatelet therapy in patients with high thrombotic and low bleeding risks through clinical cases and evidence-based recommendations.
From evidence to practice: solving complex cases with EuroIntervention
22 May 2025 – From EuroPCR 2025
Translate evidence into clinical practice with this session focusing on complex case analyses supported by EuroIntervention resources. Experience detailed presentations of challenging PCI, intracoronary imaging, coronary physiology, and TAVI cases, each followed by evidence-based solutions provided through EuroIntervention. Enhance your decision-making skills by integrating guidelines and...
Pharmacotherapy coronary interventions: new insights
22 May 2025 – From EuroPCR 2025
Stay abreast of new insights in pharmacotherapy for coronary interventions with a focus on optimizing patient outcomes. Topics include ticagrelor monotherapy in chronic coronary syndrome post-PCI, analysis of multiple events in high bleeding risk patients from the MASTER DAPT trial, effects of beta-blocker interruption in MI...
If I can’t stent it, should I care? Unmasking hidden atherosclerosis through novel imaging techniques
22 May 2025 – From EuroPCR 2025
Unveil the potential of novel imaging techniques in identifying hidden atherosclerosis and silent inflammation. This session discusses the role of perivascular adipose tissue in plaque development, highlights advances in early inflammation detection, and explores clinical management of patients with athero-inflammation beyond traditional stenting options.
Academic Research Consortium initiative on left atrial appendage closure – standardising definitions and endpoints to move forward
21 May 2025
Philippe Garot describes the EuroPCR 2025 session on left atrial appendage closure (LAAC), which offers a preview of the upcoming new consensus document developed by the Academic Research Consortium.
Author
TAVI for asymptomatic aortic stenosis after EARLY TAVI - TAVI and coronary artery disease after NOTION-3
21 May 2025 – From EuroPCR 2025
Critically assess the clinical implications of the EARLY TAVI and NOTION-3 trials with a focus on asymptomatic aortic stenosis and concomitant coronary artery disease. This session integrates recent evidence into patient-centered care pathways, offering case-based insights for optimizing timing and management strategies in TAVI patients.
Major Late-Breaking Trials from EuroPCR 2025
21 May 2025 – From EuroPCR 2025
Discover major late-breaking trials from EuroPCR 2025 in this session presenting pivotal study data. Highlights include meta-analyses from the PROTECTED TAVR and BHF PROTECT-TAVI studies, angiography versus physiology-guided PCI during TAVI (FAITAVI trial), and novel antiplatelet strategies following drug-coated stent implantation in acute coronary syndrome, with...
Optimal management of high bleeding risk patient with multivessel disease
21 May 2025 – From EuroPCR 2025
This session offers a comprehensive overview of the management of high bleeding risk (HBR) patients with multivessel disease. Through expert discussion and a live case demonstration featuring a complex elderly patient, it highlights how intracoronary imaging and physiology can guide procedural decisions and improve outcomes in this...
Academic Research Consortium on LAA closure
21 May 2025 – From EuroPCR 2025
Gain comprehensive understanding of the Academic Research Consortium's achievements in left atrial appendage (LAA) closure. Learn how standardized endpoints are streamlined for randomized controlled trials and how collaborative efforts homogenize definitions to advance clinical research.
Align for the future with the Myval Octapro transcatheter heart valve series
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a practical and evidence-based update on the Myval Octapro THV. Learn step-by-step techniques for valve-in-valve TAVI using the OctaAlign approach, and understand how intermediate sizes and precise deployment contribute to optimised hemodynamics and long-term durability.
Clinical insights are backed by key data...
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
21 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
21 May 2025 – From EuroPCR 2025
When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...
EuroIntervention Journal: 20 years of excellence
25 Feb 2025
Join the PCR community as we commemorate a big year for EuroIntervention!
In this video, your peers share why they read EuroIntervention and how it impacts their daily practice.
Author
Author
Author
Author
Author
Author
Author
Author
Author
Author
Author
Best of science and education in cardiovascular interventional medicine in 2024
16 Dec 2024
Dear Colleagues, dear PCR Companions,
As we welcome a new year, it is the perfect time to reflect on what we achieved together over the past year—both as a celebration of our successes and as motivation to continue improving in the year ahead.
2024 was a record year...
